At a glance
- Originator Abbott Laboratories
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Dopamine D1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 15 Mar 2001 No-Development-Reported for Parkinson's disease in USA (Unknown route)
- 14 Aug 1997 Preclinical development for Parkinson's disease in USA (Unknown route)